The untapped potential of Gallium 68-PET: the next wave of ⁶⁸Ga-agents.

Daniel L Smith, Wouter A P Breeman, Jennifer Sims-Mourtada

Journal: Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2013;76():14-23

PMID: 23232184

Full Text on Elsevier Science View on PubMed

Abstract

(68)Gallium-PET ((68)Ga-PET) agents have significant clinical promise. The radionuclide can be produced from a (68)Ge/(68)Ga generator on site and is a convenient alternative to cyclotron-based PET isotopes. The short half-life of (68)Ga permits imaging applications with sufficient radioactivity while maintaining patient dose to an acceptable level. Furthermore, due to superior resolution, (68)Ga-PET agents have the ability to replace current SPECT agents in many applications. This article outlines the upcoming agents and challenges faced during the translational development of (68)Ga agents.

Address: Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston TX, USA.

DOI: 10.1016/j.apradiso.2012.10.014

Link outs

Free resources

Other Literature Sources:

Subscription / membership required

Full Text Sources:

https://linkinghub.elsevier.com/retrieve/pii/S0969...

MeSH Terms: Amine Oxidase (Copper-Containing), Cell Adhesion Molecules, Gallium Radioisotopes, Glucagon-Like Peptide 1, Half-Life, Insulinoma, Neuroendocrine Tumors, Octreotide, Oligopeptides, Organometallic Compounds, Positron-Emission Tomography, Radionuclide Generators, Radiopharmaceuticals, Receptors, Bombesin, Receptors, Somatostatin, Single-Domain Antibodies, Somatostatin, Vascular Endothelial Growth Factor A